Patient-reported outcome after total hip arthroplasty: comparison between lateral and posterior approach: A randomized controlled trial in 80 patients with 12-month follow-up

Autor: Signe Rosenlund, Leif Broeng, Anders Holsgaard-Larsen, Carsten Jensen, Søren Overgaard

Publikováno v: Acta Orthopaedica, Vol 88, Iss 3, Pp 239-247 (2017)

Background and purpose — Criticism of the lateral approach (LA) for hip arthroplasty is mainly based on the risk of poor patient-reported outcomes compared to the posterior approach (PA). However, there have been no controlled studies comparing pat

Externí odkaz: https://doaj.org/article/5e7f133fe2424a78b6465d12bd5cf9f6

The Gait Deviation Index Is Associated with Hip Muscle Strength and Patient-Reported Outcome in Patients with Severe Hip Osteoarthritis-A Cross-Sectional Study.

Autor: Signe Rosenlund, Anders Holsgaard-Larsen, Søren Overgaard, Carsten Jensen

Publikováno v: PLoS ONE, Vol 11, Iss 4, p e0153177 (2016)

BACKGROUND:The Gait Deviation Index summarizes overall gait 'quality', based on kinematic data from a 3-dimensional gait analysis. However, it is unknown which clinical outcomes may affect the Gait Deviation Index in patients with primary hip osteoar

Externí odkaz: https://doaj.org/article/29be22bd068f44b9ab374d88352fc267

Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial

Autor: Verusca Lecchi, Pamela Surtees, Jessie A. Hermann, Marina Noutsou, Lidmila Francová, Francesca Lo Bue, Silvia Prandini, Annika Durban, Heidrun Wölk, Suzy van Steenderen, Gemma Currie, Rüdiger Göke, Ivan Rychlik, Daniela Cugini, Annette Busmann, Ulrike Wittkop, Svitlana Yakymchuk, John R. Petrie, Slavica S. Stratrova, Stanley M H Yeung, Julia Raad, Antonio Cannata, Ninna Hahn Tougaard, Robbie Wilson, Barbara Neuhaus, Joachim Beige, Olivera Stojceva-Taneva, Harald Mischak, Tine W. Hansen, Giulia Gherardi, Caroline Boukens-de Graaf, Renata Amanaki, Francesco Nones, Anneke K. De Bruin, Aneliya Parvanova, Elizabeth Douglas, Carolina Aparicio, Gerjan Navis, Tereza Havrdova, Alberto Ortiz, Maria Dolores Sanchez-Niño, Simone Theilade, Ferrina Clerc-de Jong, Signe Abitz Winther, Adrian M. Ramos, Regina Ax-Smolarski, Ingo Dimos, Christina M. Gant, Peter Girman, Friedrich W. Petry, Peter Rossing, Bruno Lapauw, Katarina Adamova, Rikke J. Stefansen, Michael Prigge, Mie K. Eickhoff, Petra Zürbig, Viktor Rotbain Curovic, Davide Villa, Goce Spasovski, Marian Nannings, Adriaan Kooy, Joanne Flynn, Therese Frost Lerche, Veit Zieglschmid, Flavio Gaspari, Gjulsen Selim, Marijn M. Speeckaert, Jens C. Laursen, Elsie de Man, Signe Rosenlund, Christian Delles, Giel Nijpels, Katriona Brooksbank, Alessandro Villa, Ilian Iliev, Morten Lindhardt, Maria A. Campbell, Lone Jelstrup, Gozewijn D. Laverman, Matias Trillini, Ulrike Schmidt, Kristin Kreutzmann, Silke Zimmermann, Ceyda Kilic, Tina R. Juhl, Silvia Ferrari, Nadia Stucchi, Beatriz Fernandez-Fernandez, Christian Stevns Hansen, Femke Rutters, Brenda Wierbos, Sabien Inion, Maria Lajer, Justyna Siwy, Jannet Entius, Sascha Pilemann-Lyberg, Lene Aabo, Heiko von der Leyen, Elina Eldeik, Tatjana Gjorgovski, Marie Frimodt-Møller, Isabelle Dewettinck, Maja L.D. Halkjær, Joline W.J. Beulens, Šárka Albrechtová, Stephan J. L. Bakker, Hiddo J.L. Heerspink, Brit Rädisch, Clotilde Vázquez, Ilse J. M. Hagedoorn, Dorthe Riis, Bernt Johan von Scholten, Andreas L. Birkenfeld, Kelly Rokegem, Ana Belen Sanz, Frederik Persson, Eva Bollweber, Anika Hävemeier, Frank Huvers, Petra Schutten-Westerneng, Piero Ruggenenti, Sharon Kean, Maria Á. Gonzalo, Anne G. Lundgaard, Marco Schiemann, Emilie H. Zobel, Nete Tofte, Joe Galloway, Daniela Melacini, Jinny Sanchez-Rodriguez

Publikováno v: Lancet Diabetes & Endocrinology, 8(4), 301-312. ELSEVIER SCIENCE INC
Tofte, N, Lindhardt, M, Adamova, K, Bakker, S J L, Beige, J, Beulens, J W J, Birkenfeld, A L, Currie, G, Dimos, I, Francová, L, Frimodt-Møller, M, Girman, P, Göke, R, Havrdova, T, Heerspink, H J L, Kooy, A, Laverman, G D, Mischak, H, Navis, G, Nijpels, G, Noutsou, M, Ortiz, A, Parvanova, A, Persson, F, Petrie, J R, Ruggenenti, P L, Rutters, F, Rychlík, I, Siwy, J, Spasovski, G, Speeckaert, M, Trillini, M, Zürbig, P, von der Leyen, H, Rossing, P, PRIORITY investigators & Nijpels, MGAAM 2020, ' Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY) : a prospective observational study and embedded randomised placebo-controlled trial ', The Lancet Diabetes and Endocrinology, vol. 8, no. 4, pp. 301-312 . https://doi.org/10.1016/S2213-8587(20)30026-7
Ann Transl Med
The Lancet Diabetes and Endocrinology, 8(4), 301-312. Elsevier BV
Lancet Diabet. Endocrinol. 8, 301-312 (2020)

Background: \ud Microalbuminuria is an early sign of kidney disease in people with diabetes and indicates increased risk of cardiovascular disease. We tested whether a urinary proteomic risk classifier (CKD273) score was associated with development o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c330f7cf6c46dc4a204c768eaea4bed
https://eprints.gla.ac.uk/212534/13/212534.pdf

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5):a placebo-controlled, randomised, phase 3a trial

Autor: Robert Silver, G Bedel, M Yanovskaya, Simon Heller, T Hart, A Golovach, G Cornett, A Luts, A Chang, L Lewy-Alterbaum, H Nguyen, S Hasan, Amir Tirosh, W Biggs, R Pratley, K Blaze, Ole Holm Hels, A Peskov, P Houser, E Klein, Peter Rossing, H Knoble, T Milovanova, P O'Donnell, S Folkerth, H A Frandsen, S Chandran, A Krzeminski, Richard E. Pratley, J Reed, S Sulosaari, Torben Hansen, T Donner, Jan W. Eriksson, R Jackson, N Krasnopeeva, J Pouzar, E Kazakova, J Gumprecht, Thalia Marie Blicher, E Morawski, S Nieminen, Y Shlesinger, J Parker, Klaus Levin, T Maxwell, Z Shaikh, A Nikkola, E Zhdanova, D Nabriski, T Lysenko, P Norwood, G Vagapova, K Khan, J Eriksson, M Hellgren, Ofri Mosenzon, John Strand, M Hewitt, Naim Shehadeh, B Barker, E Haddad, K Eliasson, Y Pergaeva, T Sathyapalan, M Kunitsyna, Thozhukat Sathyapalan, W Gandy, J Soufer, S Chilka, J Lawhead, P Nicol, M Benson, A Odugbesan, S Aronoff, G Gatipon, R Abramof, L Gonzalez-Orozco, C Desouza, O Mosenzon, I Beshay, H Traylor, B Snyder, Robert S. Lindsay, A Cleland, K Metsärinne, Paweł Bogdański, K Forshaw, M Sergeeva-Kondrachenko, Cyrus Desouza, M Hitz, S Plevin, K Astamirova, N Uhlenius, R Huntley, D Alpenidze, B Delgado, L Zarutskaya, Signe Rosenlund, John A. McKnight, P Levin, E Frolova, S Heller, P E Jakobsen, A Kapoor, R Busch, S Chaidarun, L Connery, S Hietaniemi, Sten Madsbad, M. Shamkhalova, S Lindmark, B Hella, L Belousova, C Mbogua, L Kargina

Publikováno v: Mosenzon, O, Blicher, T M, Rosenlund, S, Eriksson, J W, Heller, S, Hels, O H, Pratley, R, Sathyapalan, T, Desouza, C, PIONEER 5 Investigators, Abramof, R, Alpenidze, D, Aronoff, S, Astamirova, K, Barker, B, Bedel, G, Belousova, L, Benson, M, Beshay, I, Biggs, W, Blaze, K, Bogdanski, P, Busch, R, Chaidarun, S, Chandran, S, Chang, A, Chilka, S, Cleland, A, Connery, L, Cornett, G, Delgado, B, Desouza, C, Donner, T, Eliasson, K, Eriksson, J, Folkerth, S, Forshaw, K, Frandsen, H A, Frolova, E, Gandy, W, Gatipon, G, Golovach, A, Hansen, T K, Hitz, M, Jakobsen, P E, Levin, K, Madsbad, S, Nguyen, H, Parker, J, Reed, J, Rossing, P, Yanovskaya, M, Zarutskaya, L & Zhdanova, E 2019, ' Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5) : a placebo-controlled, randomised, phase 3a trial ', The Lancet Diabetes and Endocrinology, vol. 7, no. 7, pp. 515-527 . https://doi.org/10.1016/S2213-8587(19)30192-5
Mosenzon, O, Blicher, T M, Rosenlund, S, Eriksson, J W, Heller, S, Hels, O H, Pratley, R, Sathyapalan, T, Desouza, C & PIONEER 5 Investigators 2019, ' Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5) : a placebo-controlled, randomised, phase 3a trial ', The Lancet Diabetes & Endocrinology, vol. 7, no. 7, pp. 515-527 . https://doi.org/10.1016/S2213-8587(19)30192-5

Background: Oral semaglutide is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for glycaemic control in patients with type 2 diabetes. Type 2 diabetes is commonly associated with renal impairment, restricting treatment options. We ai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d569511b15de88f728dd8364203edd9
https://curis.ku.dk/ws/files/251035512/Efficacy_and_safety_of_oral_semaglutide_in_patients_with_type_2_diabetes_and_moderate_renal_impairment_PIONEER_5_accepted_version_.pdf

The effect of liraglutide on renal function: A randomized clinical trial

Autor: Jens Faber, Tine W. Hansen, Peter Hovind, Peter Rossing, Signe Rosenlund, Bernt Johan von Scholten, Frederik Persson

Publikováno v: Diabetes, Obesity and Metabolism. 19:239-247

Aims Patients with type 2 diabetes and albuminuria have high cardiorenal morbidity and mortality despite multifactorial treatment. Short-term reduction in albuminuria is considered suggestive of long-term renoprotective effects. We evaluated the rena

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ef78307ee88663ff98ebefc90114913
https://doi.org/10.1111/dom.12808